Literature DB >> 1552254

NOVACODE serial ECG classification system for clinical trials and epidemiologic studies.

P M Rautaharju1, H P Calhoun, B R Chaitman.   

Abstract

Traditional serial electrocardiogram (ECG) change classification schemes used in clinical trials such as the Minnesota Code rely on independent classification of the baseline and each follow-up or acute event ECG, whereby graded changes in the hierarchic severity level of the code signify new events such as myocardial infarction (MI). This approach suffers from classification errors caused by repeated instability at decision boundaries at each step when the baseline and each acute event ECG is classified, and various "verification rules" must be used at the end of the coding process to prevent trivial serial changes from causing large transitions in coded events. The NOVACODE algorithms for visual and computer coding of serial ECGs were designed to alleviate some of these instability problems by quantifying changes in critical waveform patterns on a continuous scale. This is achieved by determining, for each ECG coded, a Q-QS Score, ST Depression Score, ST Elevation Score and T-Wave Score, each ranging from 0 to 50. In the next step, a score is derived for ST-T evolution and this ST-T Evolution Score together with changes in Q-QS Score define criteria for a hierarchic mutually exclusive serial ECG change classification scheme that includes coding categories for Q-wave and non-Q wave MIs, equivocal Q wave evolution, evolving ischemic ST-T abnormalities, and various combinations of nonevolving Q-QS wave, and ST-T abnormalities.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1552254     DOI: 10.1016/s0022-0736(10)80041-x

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  14 in total

1.  The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

Authors: 
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

2.  Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Authors:  Anna Jovanovich; Joachim H Ix; John Gottdiener; Kim McFann; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Mark Sarnak; Michael G Shlipak; Kenneth J Mukamal; David Siscovick; Michel Chonchol
Journal:  Atherosclerosis       Date:  2013-09-13       Impact factor: 5.162

3.  Association of Sleep Apnea and Snoring With Incident Atrial Fibrillation in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Gen-Min Lin; Laura A Colangelo; Donald M Lloyd-Jones; Susan Redline; Joseph Yeboah; Susan R Heckbert; Saman Nazarian; Alvaro Alonso; David A Bluemke; Naresh M Punjabi; Moyses Szklo; Kiang Liu
Journal:  Am J Epidemiol       Date:  2015-05-13       Impact factor: 4.897

4.  The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program.

Authors:  Mercedes R Carnethon; Ronald J Prineas; Marinella Temprosa; Zhu-Ming Zhang; Gabriel Uwaifo; Mark E Molitch
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

5.  Prediction and classification of cardiovascular disease risk in older adults with diabetes.

Authors:  K J Mukamal; J R Kizer; L Djoussé; J H Ix; S Zieman; D S Siscovick; C T Sibley; R P Tracy; A M Arnold
Journal:  Diabetologia       Date:  2012-11-10       Impact factor: 10.122

6.  The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase.

Authors:  L Nelson Hopkins; Gary S Roubin; Elie Y Chakhtoura; William A Gray; Robert D Ferguson; Barry T Katzen; Kenneth Rosenfield; Jonathan Goldstein; Donald E Cutlip; William Morrish; Brajesh K Lal; Alice J Sheffet; MeeLee Tom; Susan Hughes; Jenifer Voeks; Krishna Kathir; James F Meschia; Robert W Hobson; Thomas G Brott
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-03       Impact factor: 2.136

7.  Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.

Authors:  C N Pellegrini; E Vittinghoff; F Lin; S B Hulley; G M Marcus
Journal:  Heart       Date:  2009-01-28       Impact factor: 5.994

8.  Gender-related differences in electrocardiographic parameters and their association with cardiac events in patients after myocardial infarction.

Authors:  Hanna Mieszczanska; Grzegorz Pietrasik; Katarzyna Piotrowicz; Scott McNitt; Arthur J Moss; Wojciech Zareba
Journal:  Am J Cardiol       Date:  2008-01-01       Impact factor: 2.778

9.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.

Authors:  Bernard R Chaitman; Regina M Hardison; Dale Adler; Suzanne Gebhart; Mary Grogan; Salvador Ocampo; George Sopko; Jose A Ramires; David Schneider; Robert L Frye
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

10.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

Authors:  Denise E Bonds; Michael E Miller; Richard M Bergenstal; John B Buse; Robert P Byington; Jeff A Cutler; R James Dudl; Faramarz Ismail-Beigi; Angela R Kimel; Byron Hoogwerf; Karen R Horowitz; Peter J Savage; Elizabeth R Seaquist; Debra L Simmons; William I Sivitz; Joann M Speril-Hillen; Mary Ellen Sweeney
Journal:  BMJ       Date:  2010-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.